|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among 200 outpatients with dementia and MCI, 146 outpatients with mild AD or A-MCI were recruited and divided into two genotypic groups, valine homozygosity (Val/Val) and methionine (Met) carriers, based on the representative BDNF functional polymorphism Val66Met.
|
22699449 |
2012 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Higher stride time variability was associated with falls in older adults without dementia (CHI and each MCI subgroup) and mild non-AD dementia, whereas lower gait speed was associated with falls in all participant groups, except in mild AD dementia.
|
27914848 |
2017 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCM demonstrates corneal nerve fiber loss, which is associated with a decline in cognitive function and functional independence in patients with MCI and dementia.
|
31019993 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Incidence of dementia in oldest-old with amnestic MCI and other cognitive impairments.
|
22076544 |
2011 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Four studies suggest higher prevalence of MCI and neurodegenerative disease among NFL retirees, although a quantifiable risk and prevalence of cognitive impairment and dementia in these players remains unknown.
|
31592681 |
2020 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carriers were more likely to receive scores of 0.5 or higher on the CDR (p < 0.001), and a clinical diagnosis of either MCI or dementia (p = 0.004).
|
22442429 |
2012 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Individuals who were married and those who were very satisfied with life are protected against the risk of developing MCI and dementia.
|
28269770 |
2017 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Further analysis of the diagnostic subgroups suggested different variables were more strongly associated with IADL from group to group (apathy and depression for normal participants, apathy for MCI participants and for participants with dementia due to AD, but not for those with non-AD dementia).
|
29190312 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> Linguistic features of spontaneous speech transcribed and analyzed by NLP techniques show significant differences between controls and pathological states (not only eD but also MCI) and seems to be a promising approach for the identification of preclinical stages of dementia.
|
30483116 |
2018 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among 215 outpatients with dementia and MCI, 155 with mild AD (n = 108) or A-MCI (n = 47) were recruited and divided into three genotypic groups based on the representative NT-3 functional polymorphisms rs6332 and rs6489630.
|
23075484 |
2012 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presented approach is a valuable tool for identifying patients with dementia or MCI and for supporting the clinician in the diagnostic process, by providing an outstanding support decision tool in the diagnostics of neurodegenerative diseases.
|
29054264 |
2017 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the absence of a specific phenotype, the diagnosis of MCI might identify PSP patients at greatest risk of developing dementia and should be considered further in the diagnostic assessment.
|
28881351 |
2017 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cognitive decline (defined as the incidence of either Parkinson's disease mild cognitive impairment [PD-MCI] or dementia [PDD], diagnosed according to published criteria and blinded to genotype) was studied as the primary outcome.
|
28869277 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Individuals aged 55-75 years who live in the United States and self-report not having a diagnosis of cognitive impairment such as MCI or dementia are eligible to join GeneMatch.
|
30772251 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were 38 controls, 26 patients with pure ADCI (18 mild cognitive impairment [MCI] and 8 dementia), 28 patients with pure LBCI (13 MCI and 15 dementia), and 54 patients with mixed ADCI and LBCI (17 MCI and 37 dementia).
|
30944239 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, these findings indicate that evaluating executive functions with the IFS can be valuable for the identification of MCI, a high-risk group for dementia, and for differentiating this condition from healthy aging and AD.
|
31504056 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The primary outcome was cognitive status, classified as normal, mild cognitive impairment [MCI], and dementia on the basis of standardized cognitive tests (delayed word recall, word fluency, and digit symbol substitution).
|
30030736 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia.
|
29446123 |
2018 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The proportion of A+T+N+ patients increased with syndrome severity (from 1% in SCD to 14% in MCI and 35% in dementia), while the opposite was true for A-T-N- (from 48% to 19% and 6%).
|
31597710 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Physical inactivity and executive dysfunction were associated with physical decline in this sample, which included participants with MCI and dementia.
|
29798680 |
2019 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diagnosis of dementia at follow-up (obtained using clinical diagnostic criteria) constituted the reference standard, and all the included aMCI patients were divided into two groups: the aMCI converters (MCI-C) and MCI nonconverters (MCI-NC).
|
31744965 |
2020 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cognitive function was assessed using two computer-based questionnaires (touch panel-type dementia assessment scale [TDAS] and mild cognitive impairment [MCI] screen).
|
28345266 |
2017 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Determination of YKL-40 CSF concentration may be also helpful in differentiation between types of dementia and in the distinction of patients in the stable phase of MCI from those who progressed to dementia.
|
28183245 |
2017 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In all cohorts, the strongest determinant for dementia development was the co-existence of RBD, MCI and orthostatic hypotension at baseline.
|
27911340 |
2017 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
150 individuals with ET (109 Normal Cognition (ET-NC group), and 30 with MCI and 11 dementia (ET-CI group)) completed self-ratings and objective assessments of memory, language, and executive functioning.
|
28477687 |
2017 |